Loading...
•
Sep 30, 2022
Amphastar Q3 2022 Earnings Report
Amphastar reported solid growth in Q3 2022, driven by increased sales of epinephrine, Primatene Mist®, and glucagon.
Key Takeaways
Amphastar Pharmaceuticals reported net revenues of $120.1 million for Q3 2022, a 7% increase compared to Q3 2021. GAAP net income was $15.9 million, or $0.30 per share, while adjusted non-GAAP net income was $20.2 million, or $0.38 per share. The company's growth was primarily driven by strong sales of epinephrine, Primatene Mist®, and glucagon.
Net revenues reached $120.1 million.
GAAP net income was $15.9 million, or $0.30 per share.
Adjusted non-GAAP net income was $20.2 million, or $0.38 per share.
Continued investment in capacity has successfully led to another quarter of solid growth driven by strong epinephrine, Primatene Mist®, and glucagon sales.
Revenue by Segment
Forward Guidance
The company remains optimistic that its multiple pipeline product candidates will continue to progress through their respective stages of development and will ultimately position them to deliver continued growth in the future.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...